{"title":"基于代谢性疾病生物标志物的代谢型风险聚类及其与韩国成年人代谢综合征的关联:来自2016-2023年韩国国家健康和营养检查调查(KNHANES)的发现","authors":"Jimi Kim","doi":"10.3390/diseases13080239","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome (MetS) is a multifactorial condition involving central obesity, dyslipidemia, hypertension, and impaired glucose metabolism, significantly increasing the risk of type 2 diabetes and cardiovascular disease.</p><p><strong>Objectives: </strong>Given the clinical heterogeneity of MetS, this study aimed to identify distinct metabolic phenotypes, referred to as metabotypes, using validated biomarkers and to examine their association with MetS.</p><p><strong>Materials and methods: </strong>A total of 1245 Korean adults aged 19-79 years were selected from the 2016-2023 Korea National Health and Nutrition Examination Survey. Metabotype risk clusters were derived using k-means clustering based on five biomarkers: body mass index (BMI), uric acid, fasting blood glucose (FBG), high-density lipoprotein cholesterol (HDLc), and non-HDL cholesterol (non-HDLc). Multivariable logistic regression was used to assess associations with MetS.</p><p><strong>Results: </strong>Three distinct metabotype risk clusters (low, intermediate, and high risk) were identified. The high-risk cluster exhibited significantly worse metabolic profiles, including elevated BMI, FBG, HbA1c, triglyceride, and reduced HDLc. The prevalence of MetS increased progressively across metabotype risk clusters (OR: 5.46, 95% CI: 2.89-10.30, <i>p</i> < 0.001). In sex-stratified analyses, the high-risk cluster was strongly associated with MetS in both men (OR: 9.22, 95% CI: 3.49-24.36, <i>p</i> < 0.001) and women (OR: 3.70, 95% CI: 1.56-8.75, <i>p</i> = 0.003), with notable sex-specific differences in lipid profiles, particularly in HDLc.</p><p><strong>Conclusion: </strong>These findings support the utility of metabotyping using routine biomarkers as a tool for early identification of high-risk individuals and the development of personalized prevention strategies in clinical and public health settings.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":"13 8","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12386031/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metabotype Risk Clustering Based on Metabolic Disease Biomarkers and Its Association with Metabolic Syndrome in Korean Adults: Findings from the 2016-2023 Korea National Health and Nutrition Examination Survey (KNHANES).\",\"authors\":\"Jimi Kim\",\"doi\":\"10.3390/diseases13080239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Metabolic syndrome (MetS) is a multifactorial condition involving central obesity, dyslipidemia, hypertension, and impaired glucose metabolism, significantly increasing the risk of type 2 diabetes and cardiovascular disease.</p><p><strong>Objectives: </strong>Given the clinical heterogeneity of MetS, this study aimed to identify distinct metabolic phenotypes, referred to as metabotypes, using validated biomarkers and to examine their association with MetS.</p><p><strong>Materials and methods: </strong>A total of 1245 Korean adults aged 19-79 years were selected from the 2016-2023 Korea National Health and Nutrition Examination Survey. Metabotype risk clusters were derived using k-means clustering based on five biomarkers: body mass index (BMI), uric acid, fasting blood glucose (FBG), high-density lipoprotein cholesterol (HDLc), and non-HDL cholesterol (non-HDLc). Multivariable logistic regression was used to assess associations with MetS.</p><p><strong>Results: </strong>Three distinct metabotype risk clusters (low, intermediate, and high risk) were identified. The high-risk cluster exhibited significantly worse metabolic profiles, including elevated BMI, FBG, HbA1c, triglyceride, and reduced HDLc. The prevalence of MetS increased progressively across metabotype risk clusters (OR: 5.46, 95% CI: 2.89-10.30, <i>p</i> < 0.001). In sex-stratified analyses, the high-risk cluster was strongly associated with MetS in both men (OR: 9.22, 95% CI: 3.49-24.36, <i>p</i> < 0.001) and women (OR: 3.70, 95% CI: 1.56-8.75, <i>p</i> = 0.003), with notable sex-specific differences in lipid profiles, particularly in HDLc.</p><p><strong>Conclusion: </strong>These findings support the utility of metabotyping using routine biomarkers as a tool for early identification of high-risk individuals and the development of personalized prevention strategies in clinical and public health settings.</p>\",\"PeriodicalId\":72832,\"journal\":{\"name\":\"Diseases (Basel, Switzerland)\",\"volume\":\"13 8\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12386031/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diseases (Basel, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/diseases13080239\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/diseases13080239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:代谢综合征(MetS)是一种多因素疾病,涉及中枢性肥胖、血脂异常、高血压和糖代谢障碍,显著增加2型糖尿病和心血管疾病的风险。目的:考虑到MetS的临床异质性,本研究旨在识别不同的代谢表型,称为代谢型,使用经过验证的生物标志物,并检查它们与MetS的关系。材料与方法:选取2016-2023年韩国国民健康与营养调查中19-79岁的韩国成年人1245人。代谢型风险聚类基于5个生物标志物:体重指数(BMI)、尿酸、空腹血糖(FBG)、高密度脂蛋白胆固醇(HDLc)和非高密度脂蛋白胆固醇(non-HDLc),采用k均值聚类法推导。多变量逻辑回归用于评估与MetS的关联。结果:确定了三种不同的代谢型风险集群(低、中、高风险)。高危组表现出明显较差的代谢特征,包括BMI、FBG、HbA1c、甘油三酯升高和HDLc降低。MetS的患病率在代谢型风险集群中逐渐增加(OR: 5.46, 95% CI: 2.89-10.30, p < 0.001)。在性别分层分析中,高风险集群与男性(OR: 9.22, 95% CI: 3.49-24.36, p < 0.001)和女性(OR: 3.70, 95% CI: 1.56-8.75, p = 0.003)的MetS密切相关,在脂质谱上存在显著的性别特异性差异,特别是在HDLc中。结论:这些发现支持利用常规生物标志物进行代谢分型作为早期识别高危个体的工具,并在临床和公共卫生环境中制定个性化的预防策略。
Metabotype Risk Clustering Based on Metabolic Disease Biomarkers and Its Association with Metabolic Syndrome in Korean Adults: Findings from the 2016-2023 Korea National Health and Nutrition Examination Survey (KNHANES).
Background: Metabolic syndrome (MetS) is a multifactorial condition involving central obesity, dyslipidemia, hypertension, and impaired glucose metabolism, significantly increasing the risk of type 2 diabetes and cardiovascular disease.
Objectives: Given the clinical heterogeneity of MetS, this study aimed to identify distinct metabolic phenotypes, referred to as metabotypes, using validated biomarkers and to examine their association with MetS.
Materials and methods: A total of 1245 Korean adults aged 19-79 years were selected from the 2016-2023 Korea National Health and Nutrition Examination Survey. Metabotype risk clusters were derived using k-means clustering based on five biomarkers: body mass index (BMI), uric acid, fasting blood glucose (FBG), high-density lipoprotein cholesterol (HDLc), and non-HDL cholesterol (non-HDLc). Multivariable logistic regression was used to assess associations with MetS.
Results: Three distinct metabotype risk clusters (low, intermediate, and high risk) were identified. The high-risk cluster exhibited significantly worse metabolic profiles, including elevated BMI, FBG, HbA1c, triglyceride, and reduced HDLc. The prevalence of MetS increased progressively across metabotype risk clusters (OR: 5.46, 95% CI: 2.89-10.30, p < 0.001). In sex-stratified analyses, the high-risk cluster was strongly associated with MetS in both men (OR: 9.22, 95% CI: 3.49-24.36, p < 0.001) and women (OR: 3.70, 95% CI: 1.56-8.75, p = 0.003), with notable sex-specific differences in lipid profiles, particularly in HDLc.
Conclusion: These findings support the utility of metabotyping using routine biomarkers as a tool for early identification of high-risk individuals and the development of personalized prevention strategies in clinical and public health settings.